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The pharmacological modulation of glutamatergic neurotransmission to improve cognitive 
function has been a focus of intensive research, particularly in relation to the cognitive 
deficits seen in schizophrenia. Despite this effort there has been little success in the clinical 
use of glutamatergic compounds as procognitive drugs. Here we review a selection of the 
drugs used to modulate glutamatergic signalling and how they impact on cognitive function 
in rodents and humans. We highlight how glutamatergic dysfunction, and NMDA receptor 
hypofunction in particular, is a key mechanism contributing to the cognitive deficits 
observed in schizophrenia, and outline some of the glutamatergic targets that have been 
tested as putative procognitive targets for the disorder. Using translational research in this 
area as a leading exemplar, namely models of NMDA receptor hypofunction, we discuss 
how the study of functional brain network connectivity can provide new insight into how 
the glutamatergic system impacts on cognitive function. Future studies characterising 
functional brain network connectivity will increase our understanding of how glutamatergic 






C-2-deoxyglucose; 5-CSRTT, 5-choice serial reaction time task; ADX-47273, (4-
fluorophenyl)-[(3S)-3-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl]methanone; BOLD, blood oxygen 
level-dependent response; CDPPB, 3-cyano-N-[2,5-di(phenyl)pyrazol-3-yl]benzamide; CIQ, (3-Chlorophenyl) 
[3,4-dihydro-6,7-dimethoxy-1-[(4-methoxyphenoxy)methyl]-2(1H)-isoquinolinyl]methanone; traxoprodil, 1-
[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol; CPT, continuous performance task,; 




yl]-4-oxobutanoic acid; DLPFC, dorsolateral prefrontal cortex; DMN, default mode network; DMT, 
dimethyltryptamine; DR, dorsal raphe; ERP, event related potential; EEG, electroencephalogram; EST, patients 
with established schizophrenia; FC, functional connectivity; FES, first episode schizophrenia; FEP, first episode 
psychosis; fMRI, functional magnetic resonance imaging; GLYX-13, rapastinel (Thr-Pro-Pro-Thr-NH2); HC, 
healthy control; HVLT, Hopkins verbal learning task; IFG, inferior frontal gyrus; iGluRs, ionotropic glutamate 
receptors; KA, kainite; LC, locus coeruleus; LY 2140023, (−)-(1R,4S,5S,6S)-4-amino-2-
sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid; eglumetad, (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-
dicarboxylic acid; LY 395756, (1S,2S,4R,5R,6S)-rel-2-Amino-4-methylbicyclo[3.1.0]hexane-2,6-dicarboxylic acid; 
MEG, magnetoencephalography; MFG, middle frontal gyrus; mGlu, metabotropic glutamate receptors; MMN, 
mismatch negativity; MRS, magnetic resonance spectroscopy; MTEP, 3-[2-(2-methyl-1,3-thiazol-4-
yl)ethynyl]pyridine; NA, noradrenaline; NAM, negative allosteric modulator; PAL, paired associate learning 
task; PAM, positive allosteric modulator; PANSS, positive and negative symptoms scale; PCP, phencyclidine; 
PFC, prefrontal cortex; Ro 25-6981, (αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-
piperidinepropanol maleate; basimglurant, 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-
ylethynyl]-pyridine; ROI, region of interest; RT, response time; Org 25935, 2-([(1R,2S)-6-Methoxy-1-phenyl-
1,2,3,4-tetrahydronaphthalen-2-yl]methyl-methylamino)acetic acid; SAR218645, (S)-2-(1,1-dimethyl-indan-5-
yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; SZ, schizophrenia; TUNL, trial-unique, delayed 
nonmatching to location task. Drug and molecular nomenclature conforms to the British Journal of 
Pharmacology’s Concise Guide to Pharmacology (Alexander et al., 2015). 
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The Glutamate System 
 
Glutamatergic synapses in the central nervous system (CNS), responsible for fast excitatory 
neurotransmission, play a critical role in a broad range of cognitive functions. The structure 
of glutamate synapses and the molecular mechanisms underlying glutamatergic 
neurotransmission have previously been reviewed by others in detail (Sanz-Clemente et al., 
2013; Sudhof et al., 2013; Volk et al., 2015). In mature glutamatergic synapses a vast array 
of proteins are involved in the packaging of glutamate into synaptic vesicles, the localisation 
of these vesicles to presynaptic active zones and the docking and release of the contents of 
these vesicles into the synaptic cleft (Sudhof et al., 2013). Post-synaptically, glutamate acts 
at both ionotropic glutamate receptors (iGluRs), including the α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA), kainate (KA) and N-methyl-D-aspartate (NMDA) 
receptors, and metabotropic G-protein coupled glutamate (mGlu) receptors, to cause 
depolarisation in the post-synaptic neuron. mGlus are also present on the synaptic bouton 
that play an important role in the regulation of glutamate release as autoreceptors (see 
Niswinder & Conn, 2010 for review). The synaptic concentration of glutamate is also 
regulated by glutamate uptake, into both neurons and glial cells, mediated by a range of 
glutamate transporters (for review see Vandenberg and Ryan, 2013) and the 
cystine/glutamate antiporter (System Xc, Bridges et al., 2012). Much research has been 
dedicated to elucidating the roles of these molecular components in the regulation of 
cognitive and brain function, in part due to the proposed central involvement of glutamate 
system dysfunction in a broad range of brain disorders with prominent cognitive deficits 
including schizophrenia (SZ) (Coyle et al., 2006), bipolar disorder (McCloud et al., 2015), 
major depressive disorder (deWilde et al., 2015), autism spectrum disorders (Volk et al., 
2015) and Alzheimer’s Disease (Lin et al., 2014).  
The role of the N-methyl-D-aspartate (NMDA) receptor  in cognition 
NMDA receptors are tetrameric structures assembled from two obligatory GluN1 subunits 
(formerly NR1) and two GluN2 (2A-D, formerly NR2A to NR2D) subunits. NMDA receptors 
may also contain GluN3 subunits, which are particularly abundant during early life and 
appear to have a role in limiting synapse maturation. The persistence of GluN3A-containing 
NMDA receptors into adulthood may contribute to the synaptic dysfunction in psychiatric 
disorders (Perez-Otano et al., 2016), while the potential role of GluN3B is yet to be 
elucidated. 
Diversity in NMDA receptor subunit composition results in functional and pharmacological 
diversity, as exemplified by the differing pharmacology of GluN2A versus GluN2B containing 
NMDA receptors (Smith et al., 2011). The contribution of the different NMDA receptor 
subtypes to cognition is relatively poorly defined. However, recent studies in genetically 
modified mice have proved useful in further elucidating the complex relationship that exists 
between NMDA receptors with specific subunit compositions, their cellular and brain region 
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localisation and distinct cognitive functions (Table 1). In addition to these studies a 
multitude of pharmacological studies conducted in rodents, non-human primates and 
human participants have characterised the role of the NMDA receptor in cognition. Here we 
briefly review the general insights gained from these pharmacological studies. 
Evidence from pharmacological studies in rodents 
The impact of acute NMDA receptor antagonist administration 
  
Acute administration of NMDA receptor antagonists, such as ketamine, phencyclidine (PCP) 
and dizocilpine, have been shown to negatively impact on domains of executive function in 
rodents, impairing cognitive flexibility (de Bruin et al., 2013; Gastambide et al., 2013) and 
disrupting attentional processing (Barnes et al., 2016; Thomson et al., 2011). Acute NMDA 
receptor antagonist administration also negatively impacts on other cognitive domains 
impairing spatial reference learning and memory (for review see Morris, 2013; Duan et al., 
2013; Ihalainen et al., 2016), short term object recognition memory (Cloke & Winters, 2015; 
Rajagopal et al., 2015), associative memory (as assessed in the paired associates learning 
task, Kumar et al., 2015; Lins et al., 2015) and episodic learning and memory (Bast et al., 
2005) in rodents. Acute NMDA receptor antagonist administration can also induce 
motivation deficits and motor impairments, which could potentially confound some of these 
cognitive measures (Noda et al., 2000). However, the impact of these drugs on cognitive 
performance can be assessed at doses and time points after administration where these 
confounding effects are absent. A key consideration in these acute NMDA receptor 
antagonist studies, as with all pharmacological studies involving drugs targeting the 
glutamate system, is the importance of the temporal effects of each compound. These 
effects may contribute to some of the different behavioural and neural effects observed 
between different studies. Another concern is the non-selective pharmacology of the 
compounds used. For example, PCP also acts at nicotinic acetylcholine receptors (Fryer and 
Lukas, 1999) and dopamine (D2) receptors (Seeman et al., 2009) while ketamine binds to a 
wide range of non-glutamatergic targets (for review see Mion and Villevielle, 2013). Thus 
genetic studies and studies using more pharmacologically selective compounds have been 
instrumental in further supporting a key role for the NMDA receptor in cognition.  
The impact of prolonged NMDA receptor hypofunction 
 
A multitude of studies have characterised the effects of prolonged NMDA receptor 
hypofunction (induced by repeated, intermittent NMDA receptor antagonist treatment) on 
various cognitive functions in rodents. Cognitive testing in these studies is usually 
undertaken when animals are not experiencing the acute effects of these antagonists (i.e. 
when “drug free”). Thus the cognitive deficits present are thought to result from the 
plasticity changes that occur in the brain as a result of prolonged NMDA receptor 
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hypofunction. These plasticity effects include modifications in the function of non-
glutamatergic neurotransmitter systems (Jentsch, et al., 1998; Lindefors, et al., 1998), 
including the function of parvalbumin positive (PV+) GABAergic interneurons (Bygrave, et 
al., 2016), changes in synaptic plasticity (Nomura, et al., 2016), alterations in regional 
neuronal activity, including prefrontal cortex (PFC) hypofunction (Dawson et al., 2012), and 
altered brain network connectivity (see later discussion). In these studies, prolonged NMDA 
receptor antagonism has been shown to induce deficits in cognitive flexibility (Dawson et al., 
2012; McLean et al., 2012), attentional processing (Thomson et al., 2011; Barnes et al., 
2016), spatial reference learning and memory (Didricksen et al., 2007), working memory 
(Seiller & Giuffrida, 2009) and short-term object recognition memory (Pyndt Jorgensen et 
al., 2015; Horiguchi et al., 2013; Rajagopal et al., 2016). While the translational relevance of 
some of these behavioural tests to aspects of human cognition is in question (Kas, et al., 
2014; Pratt et al., 2012; Pryce & Seifritz, 2011), the overall findings implicate a central role 
for the NMDA receptor in a broad range of cognitive processes. 
 
In addition to these studies, conducted in adult animals, the impact of pharmacologically 
induced NMDA receptor hypofunction at specific developmental time points (either in 
utero, during early postnatal development or during adolescence) on cognitive function in 
the fully developed animal has also been assessed (Broberg et al., 2008; Li et al., 2011; Zhao 
et al., 2014). These studies highlight the neurodevelopmental role of NMDA receptor 
activity, at defined epochs of brain development, in “setting up” the brain for effective 
cognitive function. This area of research certainly warrants further systematic investigation. 
Insights from studies using NMDA receptor subtype selective drugs 
 
Pharmacological studies have also attempted to elucidated the role of specific NMDA 
receptor subtypes in cognition. For example, the distinct pharmacology of GluN2A versus 
GluN2B containing NMDA receptors has allowed the recent characterization of the role of 
these receptor subtypes in different cognitive functions. The GluN2A-selective antagonist 
NVP-AMM077 has recently been shown to decrease accuracy in a task assessing sustained 
attention (5-choice serial reaction time task, 5-CSRTT (Smith et al., 2011)), but has little 
effect on location discrimination, paired associate learning (PAL) and working memory (as 
assessed using the trial-unique, delayed nonmatching to location (TUNL) task (Kumar et al., 
2015)). By contrast, GluN2B-selective antagonists, such as Ro 25-6981 and Traxoprodil, 
appear to improve accuracy and processing speed in the 5-CSRTT (Higgins, et al., 2005; 
Smith, et al., 2011). However, antagonism of GluN2B using ifenprodil has been shown to 
impair performance in response time in the 5-CSRTT (Higgins, et al., 2005). This conflicting 
finding, compared to the effects of other GluN2B antagonists, may be due to non-selective 
actions of ifenprodil or its relative weak affinity for GluN2B containing NMDA receptors. 
Further NMDA receptor subtype specific effects are supported by the observation that 
traxoprodil administration impairs location discrimination but not working memory in the 
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TUNL task (Kumar et al., 2015). In addition, Ro 25-6981 ameliorates the impact of ketamine 
treatment on cognitive flexibility (assessed using the attentional set-shifting task (ASST), Kos 
et al., 2010), supporting a primary role for GluN2B containing NMDA receptors in the impact 
of ketamine on cognitive flexibility. 
 
There are a lack of studies reporting the cognitive impact of GluN2C and GluN2D -selective 
compounds. While GluN2C/D-selective compounds, such as the inhibitor DQP-1105 (Acker, 
et al., 2011), are available their effects on cognition have not yet been tested. However, 
evidence for the role of GluN2C/D containing NMDA receptors in cognitive function is 
supported by studies conducted in genetically modified mice (Table 1). In addition, 
GluN2C/D containing NMDA receptor play an important role in the effects of the NMDA 
receptor antagonists ketamine and memantine (Kotermanski & Johnson, 2009), which may 
include their effects on cognitive functions. In addition, the absence of either GluN2C or 
GluN2D have been shown to have differential effects on the cortical oscillations induced by 
NMDA receptor blockade (Gupta, et al., 2016; Sapkota, et al., 2016). Other evidence 
supporting a role for GluN2C/D containing NMDA receptors in cognitive function comes 
from studies using positive allosteric modulators (PAMs), such as CIQ and D-cycloserine, 
discussed later in this review.  
Insights from studies in genetically modified mice 
 
A range of studies have used genetically modified mice to further determine the role of the 
different NMDA receptor subtypes in a range of cognitive functions (Table 1). These studies 
are often able to extend the understanding gained from relevant pharmacological studies, in 
part due to the greater assurance of NMDA receptor subtype specificity, but also by 
targeting either specific brain subsystems (GluN1; Rompala et al., 2013; Taylor et al., 2014) 
or cell populations (GluN1 in PV+ interneurons; Bygrave et al., 2013). A limitation of these 
genetic studies is the neurodevelopmental role of NMDA receptors in the development of 
effective cognitive function, as highlighted by the persistent effects of non-selective NMDA 
receptor antagonists when selectively administered as specific developmental timepoints 
(Broberg et al., 2008; Li et al., 2011; Zhao et al., 2014). Thus, the observed effects may be 
very different from those elicited by acute pharmacological regulation of these receptor 
subtypes. Nevertheless, studies using both genetic and pharmacological approaches offer 
complementary strategies to further elucidating the role of specific NMDA receptors 
subtypes in cognition, with modern genetic approaches offering new levels of granular 
neural system, temporal and cell-type resolution. 
The NMDA receptor hypofunction hypothesis of schizophrenia 
 
The ‘glutamate hypothesis of SZ’ posits that glutamatergic system dysfunction is a key 
pathophysiological mechanism contributing to the clinical symptoms seen in patients with 
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SZ (Luby et al. 1959; Carlsson et al. 2000; Farber et al. 2002; Javitt, 2007; Javitt et al. 2012). 
The ‘NMDA receptor hypofunction hypothesis of SZ’, a more specific theory of the 
glutamate dysfunction hypothesis, has its origins in the observation that the acute 
administration of the NMDA receptor antagonists, such as ketamine and PCP, induce 
psychotic-like symptoms (delusions and hallucinations) in healthy controls (HC) that are 
similar to those seen in patients with SZ (Krystal et al. 1994; Abi-Saab et al. 1998). In 
addition, individuals who chronically abuse PCP (presumably inducing repeated intermittent 
NMDA receptor hypoactivity) show deficits in executive function similar to those seen in 
patients (Cosgrove et al. 1991). These observations have led to the development of two 
distinct but overlapping models of the glutamate hypothesis of SZ: (i) the ‘prolonged NMDA 
receptor hypofunction model’ and (ii) the ‘acute NMDA receptor hypofunction model’. 
The ‘prolonged NMDA receptor hypofunction model’ postulates that prolonged 
hypoactivation of the NMDA receptor induces multiple pathological mechanisms involved in 
the disorder (Coyle, 2006; Coyle et al. 2010; Moghaddam and Krystal, 2012; Javitt et al. 
2012) and that NMDA receptor hypofunction may be the final pathophysiological pathway 
for the positive, negative and cognitive symptoms experienced by patients with SZ (Carlsson 
et al. 1999; Goff and Coyle, 2001; Coyle, 2006; Javitt, 2010; Balu and Coyle, 2015). The 
‘acute NMDA receptor hypofunction model’ originates from clinical trials when ketamine 
was administered to HCs. Early findings found that changes in glutamatergic signalling could 
explain the psychotomimetic effects of ketamine and PCP in terms of the positive symptoms 
present in individuals with first episode SZ (FES) or first episode psychosis (FEP) (Krystal et 
al. 1994; Krystal et al. 1999; Khlestova et al. 2016). While the findings from the acute 
ketamine administration model have particularly increased our understanding of the 
positive and negative symptoms seen in patients with SZ, evidence for translationally 
relevant alterations in cognitive functions is more limited. We outline some of these 
exemplary cognitive studies below and outline their translational alignment to observations 
made in patients with SZ. 
Evidence from pharmacological studies in human participants 
In HC acute ketamine administration has been shown to significantly impact on a range of 
cognitive functions, with the effects being similar to those seen in patients with SZ. Low 
dose ketamine administration (100 ng/mL of plasma) impacts on contingency learning in HC 
when assessed using a probabilistic learning task (Vinckier et al., 2016), with ketamine 
administration inducing misleading cue-outcome associations. These findings contrast with 
those reported in an early study where the same dose of ketamine (100 ng/mL of plasma) 
failed to alter task performance (Corlett et al., 2006).  However, both studies did show 
similar effects of ketamine on blood oxygen level-dependent (BOLD) responses (increased) 
in regions of the PFC of participants undertaking the task. Deficits in contingency learning as 
well as increased BOLD responses in the PFC have also been reported in patients with SZ 
(Diaconescu et al., 2011). However, decreased BOLD responses in the PFC of patients with 
7 
SZ during contingency learning have also been reported (Dowd et al., 2016). In addition, 
increased BOLD responses in a range of other brain regions have also been reported in SZ 
patients undertaking this task (Diaconescu et al., 2011; Park et al. 2015; White et al. 2015) 
that are different from those seen in ketamine fMRI studies in HC. It is important to note 
that different temporal effects of drug administration may contribute to some of the 
divergent findings in behavioural performance and neural function reported in these clinical 
studies.  
 
Ketamine administration has also been shown to significantly impact on working and 
declarative memory in HC. Ketamine administration significantly reduced accuracy in the 
continuous performance task (CPT) and impairs both immediate and delayed recall in the 
Hopkins verbal learning task (HVLT, Krystal et al., 2005). The effect of ketamine on working 
memory function was confirmed by another study (Honey et al., 2008). The effects of 
ketamine on working and declarative memory tasks are similar to those seen in patients 
with SZ (Blokland et al. 2016; Green et al. 2016). However, the impact of ketamine on BOLD 
responses during working memory and declarative memory tasks in HC are more difficult to 
corroborate with the fMRI findings seen between SZ patients and HC, where both increased 
and reduced BOLD responses are observed in patients with SZ when compared to HC 
(Brown and Thompson, 2010; Dauvermann et al. 2014). While Anticevic et al. 2012 and 
Driesen et al. 2013 reported reduced BOLD responses in the dorsolateral PFC (DLPFC) and 
precuneus in HC treated with ketamine and SZ patients during working memory 
performance, the findings by Honey et al. 2008 (increased BOLD responses in the basal 
ganglia and thalamus of HC treated with ketamine during the task) are more difficult to align 
with observations made in patients with SZ. 
 
Ketamine administration has also been shown to impact on attentional processing, when 
assessed using both visual and auditory tasks. In HC ketamine was found to significantly 
reduced the response time to target stimuli in a visual oddball task assessing attentional 
processing (Watson et al., 2009), an effect that is similar to the reduced visual processing 
speed seen in patients with SZ (Urban et al., 2008). Similarly, in HC ketamine (0.24 mg/kg) 
also impacts on attentional processing when assess using an auditory processing task, 
increasing the number of false alarms during the task (Umbricht et al., 2000). In addition, in 
this study ketamine administration was also found to reduce the peak amplitude of the 
Mismatch Negativity (MMN) signal, an aspect of the event-related potential (ERP) detected 
using electroencephalogram (EEG) that is indicative of the arrival of an odd stimulus in a 
sequence of stimuli. Similar cognitive effects were independently observed when using both 
a low and high dose of ketamine, with only the higher dose inducing significant deficits in 
MMN (Heekeren et al., 2008). The deficits in auditory attentional processing and MMN seen 
under ketamine administration are similar to those reported in patients with SZ (Milovan et 
al., 2004). Summary outlines of these studies are provided in Table 2. 
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The impact of NMDA receptor co-agonists and partial agonists on cognition 
Much research has been dedicated to elucidating the procognitive potential of activating 
NMDA receptors, with positive modulation rather than agonism (which risks inducing 
excitotoxicity) being a key area of research. The glycine site on NMDA receptor provides an 
attractive drug target because of its positive modulatory effects on NMDA receptor 
signalling. The amino acid derivatives D-serine and D-cycloserine act as partial agonists at 
this site (Mothet et al., 2000; Watson et al., 1990). The therapeutic potential of NMDA 
receptor positive modulators in schizophrenia patients has been reviewed previously 
(Kantrowitz & Javitt, 2010; Balu & Coyle, 2015; Goff, 2012). Here we highlight and discuss 
recent findings of rodent and human studies featuring these drugs with a particular focus on 
cognition and, where applicable, summarise neuroimaging findings from rodent and human 
studies. 
Pharmacological studies in rodents 
 
In rodent studies both D-serine and D-cycloserine have been shown to have procognitive 
effects. For example, D-cycloserine improves short term object recognition, potentiates 
contextual and cued fear extinction learning in rats (Sugiyama, et al., 2015; Walker, et al., 
2002) and improves spatial learning in aged rats (Baxter et al., 1991). In addition, 
intrahippocampal D-cycloserine administration has been shown to reverse dizocilpine 
induced impairments in working memory performance in the radial arm maze (Kawabe, et 
al., 1998), suggesting that D-cycloserine administration can reduce the impact of acute 
NMDA receptor hypofunction on working memory. Similar effects have been shown for D-
serine, which improves working memory performance in the T-maze alternation test and 
enhances novel object recognition, while also reversing the long-term memory deficits 
induced by dizocilpine (Bado, et al., 2011). In addition, the recently developed tetrapeptide 
GLYX-13, a partial agonist of the NMDA receptor glycine site, has also been shown to 
improve learning and memory in young and aged rats (Burgdorf et al., 2011) as well as 
restoring object recognition in mouse models of acute and prolonged NMDA receptor 
hypofunction (Rajagopal et al., 2016). 
 
D-cycloserine demonstrates greatest efficacy at NMDA receptor containing GluN2C subunits 
(Ogden, et al., 2014) suggesting a central role for this NMDA receptor subtype in its 
procognitive effects. Potentiation of GluN2C/D–containing NMDA receptors using CIQ has 
been shown to facilitate fear learning and extinction in mice (Ogden, et al., 2014), and 
reverses the deficit in working memory (spontaneous alternation test) in mice following 
acute dizocilpine administration (Suryavanshi et al., 2014). A role for GluN2C subunit 
containing NMDA receptors in working memory is further supported by observations in 
GluN2C knockout mice (Hillman et al., 2011, Table 1). Interestingly, these mice do not show 
deficits in spatial reference memory which contrasts with the ability of D-cycloserine to 
9 
improve spatial reference memory in aged rats (Baxter et al., 1994). This suggests that the 
activity of D-cycloserine at other NMDA receptor subtypes may be more important for its 
effects on spatial reference memory, or that developmental adaptations prevent the impact 
on GluN2C knockout on spatial reference memory in GluN2C knockout mice. 
Evidence from pharmacological studies in humans 
 
In contrast to rodent studies supporting the procognitive potential of NMDA receptor partial 
agonism the evidence from studies in humans, including studies in patients with SZ, is less 
persuasive. In HC, glycine administration does not improve general cognitive performance 
on the CogState test battery (Neumeister et al., 2006) or in a visual attention task (O’Neill et 
al., 2011). Furthermore, D-cycloserine administration does not improve motor sequence 
learning in HC (Gunthner et al. 2016). By contrast, initial studies undertaken in a small 
sample of 12 HC males support a significant effect of the glycine transporter inhibitor Org 
25935 on verbal learning and delayed recall, but not on any of the other cognitive tests 
employed (D’Souza et al., 2012). More recently, Org 25935 administration was also shown 
not to improve performance in a visuo-spatial task, a working memory task or a verbal 
memory task in HC (Christmas et al., 2016). This suggests that the procognitive potential of 
these compounds in HC may be limited. Given that NMDA receptor function may be optimal 
in HC, it may be considered unsurprising that these compounds fail to significantly improve 
cognitive performance in these studies. Despite these findings one might still predict that 
these compounds would have procognitive potential in patients with brain disorders 
thought to involve NMDA receptor hypofunction, such as patients with SZ. However, studies 
investigating the procognitive potential of drugs that positively modulate NMDA receptor 
activity in patients with SZ are negative overall. For example, D-cycloserine adjunctive 
treatment does not improve composite scores of general cognitive function, or most 
individual cognitive domain scores when assessed using standardised neuropsychological 
batteries, in patients with established SZ (EST) (Buchanan et al. 2007; Goff et al. 2005; Goff 
et al. 2008; Weiser et al. 2012; Cain et al. 2014). D-cycloserine treatment also fails to 
improve performance in the CPT and working memory tasks in patients with EST (Duncan et 
al., 2004). However, there are also positive findings where D-cycloserine improved cognitive 
performance following a cognitive remediation programme in patients with EST (Cain et al., 
2014) and D-cycloserine has been shown to facilitate fear extinction therapies in people 
with anxiety disorders (Norberg et al. 2008). These findings suggest that D-cycloserine may 
yet hold therapeutic value by potentiating the efficacy of cognitive behavioural therapies, at 
least in some cognitive domains. Despite this suggestion, overall findings from recent meta-
analysis do not support the procognitive efficacy of compounds potentiating NMDA 
receptor activity in SZ. While, Tsai and Lin, (2010) found a positive impact of NMDA receptor 
enhancing agents (D-cycloserine, glycine and sarcosine) on cognitive symptoms in patients 
with SZ (assessed using the PANSS cognitive subscale), two more recent meta-analyses 
found no effect (Choi et al. 2013; Iwata et al. 2015). Choi et al., (2013) found that D-
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cycloserine, D-serine and the AMPA receptor PAM CX516, as adjunctive treatments, did not 
significantly improve function in five cognitive domains (Choi et al. 2013). Furthermore, 
Iwata et al. found no significant effect for NMDA receptor glycine site drugs in eight 
cognitive domains (Iwata et al. 2015). Thus any procognitive effects of NMDA receptor 
glycine site modulators in patients with SZ are yet to be robustly established. One reason for 
the disparity between preclinical and clinical studies may be the testing of these compounds 
as adjunctive treatments in patients, while preclinically their procognitive efficacy has not 
been tested in the context of prolonged antipsychotic administration (Summary information 
from these studies is outlined in Table 3). Furthermore, clinical efficacy has only been tested 
in patients with EST and whether these drugs would be beneficial during earlier stages of 
the disease, such as in FES patients, has not yet been adequately tested. The temporal 
relevance of NMDA receptor hypofunction, and thus the procognitive potential of 
enhancing NMDA receptor signalling, over the time course of disease progression needs to 
be much more clearly defined. Finally, the relatively short treatment duration used in some 
clinical trials, typically between 4 to 24 weeks (Choi et al. 2013) with one study at a more 
lengthy 36 weeks (Iwata et al. 2015; Table 3), may also have contribute to the overall 
negative findings. 
 
The role of AMPA-Rs in cognition 
 
AMPA receptors are heterotetramers formed from distinct subunits (GluA1-4) or as Ca
2+
-
permeable homotetramers composed of GluA1 subunits (for review see Henley and 
Wilkinson, 2016). AMPA-R expression and trafficking is a highly dynamic process, regulated 
by neuronal activity, and they play a central role in neuronal plasticity. PAMs of AMPA-Rs 
typically potentiate the channel-open state of the receptor upon glutamate activation, 
enhance long-term potentiation (LTP) and have varying effects on long-term depression 
(LTD), depending on the class of compound (Arai & Kessler, 2007). Promising results from 
early studies reported that PAMs improve cognitive function in human participants and in 
rodents. For example administration of the AMPA receptor PAM CX516 improved 
associative and recognition memory performance in HC (Ingvar et al., 1997). AMPA receptor 
PAMs have also been reported to improve cognitive performance in aging healthy 
participants, in measures such as delayed recall performance (Lynch et al., 1997) and 
working memory (Wezenberg, et al., 2007). These findings are corroborated in rodent 
studies, where administration of a benzamide AMPA receptor PAM improved performance 
in discriminative and spatial memory tasks in rats (Staubli, et al., 1994). Rodent research has 
also shown the drug reverses cognitive deficits in subchronic PCP rodent models, relevant to 
SZ, in behaviours such as attentional set-shifting (Broberg, et al., 2009) and novel object 
recognition (Damgaard, et al., 2010). However, CX516 was shown to be ineffective in 
improving deficits in cognitive flexibility and working memory seen in patients with SZ, when 
given as an adjuvant with antipsychotic drugs (Goff, et al., 2008). Therefore, the therapeutic 
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potential of AMPA receptor PAMs in SZ requires further investigation. 
The role of metabotropic glutamate receptor subtypes 2 and 3 (mGlu2 and mGlu3) in 
cognition 
Numerous studies have demonstrated efficacy of mGlu2/3 agonists and PAMs in reversing 
cognitive dysfunction in animal models. For example, mGlu2/3 agonists improve acute PCP-
induced working memory deficits (Eglumetad; Moghaddam & Adams, 1998), deficits in 
working memory and latent inhibition in GluN1 knockout mice (SAR218645; Griebel, et al., 
2016), and novel object recognition performance in a post-weaning social isolation rat 
model (LY379268; Jones, et al., 2011). In addition, the mGlu2  selective PAM was shown to 
improve cognitive flexibility in control rats (Nikiforuk et al., 2010). However, some studies 
have failed to reproduce these findings, and also show that mGlu2/3 agonists may actually 
worsen some aspects of cognition, including working memory, when given alone (Eglumetad 
in rodents and marmosets; Schlumberger, et al., 2009; Spinelli, et al., 2005) or have no 
significant effect in control animals (LY395756; Li et al., 2015). Therefore, these compounds 
may only be effective in improving cognition in states of glutamatergic dysfunction. 
In human studies mGlu2/3 receptor agonists have provided some promising results in 
improving cognitive performance. For example, LY2140023 demonstrated encouraging 
results in treating positive and negative symptoms in patients with SZ (Patil, et al., 2007) but 
ultimately the drug failed to pass Phase III clinical trials (Adams, et al., 2014). Unfortunately, 
the procognitive effects of this drug in patients were not assessed and the putative 
procognitive effects of mGlu2/3 PAMs in SZ is yet to be firmly established. 
The role of metabotropic glutamate receptor subtype 5 (mGlu5) in cognition 
In disorders thought to involve NMDA receptor hypofunction, such as SZ, drugs active at 
mGlu5 receptors have been proposed as potential therapeutics, due to close functional 
coupling between the two receptors and the ability of mGlu5 activation to potentiate NMDA 
receptor activity (Awad et al., 2000; Pisani et al., 2001). A key focus of research has been on 
PAMs of the mGlu5 receptor, drugs that act by binding to an allosteric site on the receptor 
to potentiate its activation by glutamate (CPPHA; Chen et al., 2008; CDPPB; Uslaner et al., 
2009). In unimpaired (control) rodents mGlu5 PAMs have been shown to improve object 
recognition memory (ADX47273; Liu, et al., 2008; CDPPB; Uslaner et al., 2009), spatial 
learning (CDPPB and ADX47273; Ayala et al., 2009), contextual fear acquisition (DFPE; 
Gregory et al., 2013) and extinction learning (CDPPB; Cleva et al., 2011). In rodents mGlu5 
PAMs have also been shown to limit the impact of NMDA receptor antagonists on cognition. 
For example CDPPB reverses the dizocilpine induced deficits in NOR (Uslaner et al., 2009) 
and cognitive flexibility, assessed using the ASST (Darrah, et al., 2008; LaCrosse, et al., 2015). 
The mGlu5 PAM ADX47273 has also been shown to decrease premature responding in the 5-
CSRTT test of impulsivity in trait-impulsive rats, and attenuates the increased impulsiveness 
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in rats following dizocilpine administration (Isherwood, et al., 2015). These procognitive 
effects are thought to be mediated by the ability of mGlu5 PAMS to enhance synaptic 
plasticity, through both the enhancement of LTP and LTD (Ayala et al., 2009; Xu, et al., 
2013). However, while some of these effects may be dependent on the interaction of mGlu5 
with the NMDA receptor, others may be independent from this interaction (Rook et al., 
2015). 
There is also evidence of cognitive improvement with negative allosteric modulation (NAM) 
of mGlu5 receptors. For example, CTEP reverses an inhibitory avoidance deficit in mice with 
16p11.2 microdeletion (Tian, et al., 2015). However, injection of the mGlu5 antagonist MPEP 
into the lateral ventricles of control rats prior to training impairs working memory 
performance in the radial arm maze (Manahan-Vaughan & Braunewell, 2005) and systemic 
pretreatment exacerbates dizocilpine-induced deficits in spatial working memory 
(Homayoun, et al., 2004). The mGlu5 NAMs, basimglurant and MTEP, also impair 
performance in the 5-CSRTT in control animals (Isherwood, et al., 2015). Overall these data 
suggest that an optimal level of mGlu5 activity is required for effective cognition and the 
preclinical research suggests that mGlu5 receptors may be a promising therapeutic target to 
improve cognitive deficits, at least in some disorders. However, research in human subjects 
has yet to demonstrate the impact of mGlu5-selective drugs on cognition (Berry-Kravis, et 
al., 2016). 
Glutamatergic regulation of functional brain network connectivity: insights from 
pharmacological studies targeting the NMDA receptor 
 
The study of how drugs targeting the glutamate system alter functional brain network 
connectivity to influence cognition is in its extreme infancy. However, recent data from 
studies characterising the impact of NMDA receptor antagonists on brain network 
connectivity have given new insight into the glutamatergic regulation of brain connectivity. 
In addition, these studies have highlighted the potential translational value of the analysis of 
brain network connectivity, with the reported effects appearing to be conserved between 
species (rodents, primates and humans) and across imaging modalities, in measures of brain 
network connectivity. Here, we provide a brief overview of the studies that have 
characterised the impact of NMDA receptor antagonists on functional brain network 
connectivity. The results highlight the potential future utility of this approach in studying 
other manipulations of the glutamate system, whether they be pharmacological or genetic, 
that are known to impact on cognition. 
Insights from rodent studies characterising the impact of NMDA receptor antagonists on 
functional brain network connectivity 
 
Acute treatment with a subanaesthetic dose of ketamine induces abnormal increases in 
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functional brain network connectivity as analysed using 
14
C-2-deoxyglucose functional brain 
imaging (Dawson et al., 2014). Ketamine treatment increases the number of functional 
connections and alters the topographic properties of functional brain networks to increase 
clustering between local brain regions. This suggests that subanaesthetic ketamine 
treatment impacts on cognition by promoting abnormally enhanced functional connectivity 
in local subsystems. From a neural subsystems perspective, this includes abnormally 
increased local functional connectivity between subfields of the prefrontal cortex (Dawson 
et al., 2013), which parallels the PFC regional hyperconnectivity induced by subaneasthetic 
ketamine treatment in primates (Gopinath et al., 2016) as well as during resting-state in 
humans (Anticevic, et al., 2015). By contrast, subanaesthetic ketamine treatment in rats 
impairs long range connectivity, including for example decreased PFC functional 
connectivity to thalamic inputs (Dawson et al., 2013; 2014). This suggests that ketamine 
treatment both compromises the ability of the PFC to receive information from other neural 
subsystems and that enhanced local clustering within the PFC compromises the appropriate 
segregation of the information received at the local level. These two mechanisms may 
contribute to the impact of ketamine of PFC-dependent cognitive processes in rodents 
(Nikiforuk & Popik, 2014; Nikiforuk et al., 2016). In addition, functional connectivity 
between neuromodulatory subsystems such as the dorsal raphe nucleus (DR), the origin of 
serotonergic (5-HT) innervation, and the locus coeruleus (LC), the origin of noradrenergic 
(NA) innervation to the PFC are abnormally enhanced by acute NMDA receptor blockade 
(Dawson et al., 2013; 2014). Both 5-HT and NA are known to modulate PFC-dependent 
cognitive processes (Berridge & Spencer, 2016; Clarke et al., 2007). Thus, the modification of 
the connectivity between neuromodulatory subsystems and the PFC may be a key 
mechanism contributing to the impact of acute NMDA receptor blockade on cognition, in 
addition to the local effects of ketamine in the PFC and other cognitive neural subsystems 
(e.g. hippocampus). The disruption of thalamo-cortical connectivity is a major impact of 
acute NMDA receptor antagonist treatment, with the thalamic reticular nucleus being a 
particularly important target (for review see Pratt et al., 2015). Interestingly, disrupted 
thalamocortical connectivity is found both in rodents treated with ketamine, when brain 
networks are analysed using 
14
C-2-DG, and in human participants treated with ketamine 
when analysed using resting-state magnetoencephalography (MEG, Rivolta et al., 2015), 
supporting not only the conservation of alterations in functional connectivity (FC) across 
species but also across different imaging modalities. This conservation may be key to 
facilitating translation in the context of identifying procognitive glutamate system targeting 
drugs.  
 
In contrast to the effects of acute NMDA receptor blockade, prolonged NMDA receptor 
hypofunction, as induced by subchronic PCP treatment induces compromised functional 
brain network connectivity in rodents (Dawson et al., 2012; 2014). At the global network 
scale this results from a decreased number of functional connections in the brain network, 
decreased clustering and an increase in the number of functional connections that must be 
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traversed to reach one brain region to another (a measure known as average pathlength, 
Dawson et al., 2014). These global alterations strongly parallel those reported in functional 
resting-state brain networks of EST (Li et al., 2008; Micheloyannis et al., 2006), supporting 
the translational potential of these network measures. Subchronic PCP treatment also 
results in decreased thalamic, hippocampal and PFC connectivity, and induces a decrease in 
the functional integration between the hippocampus and PFC (Dawson et al., 2012), which 
could contribute to the cognitive deficits seen as a result of prolonged NMDA receptor 
hypofunction. Decreased hippocampal-PFC resting-state functional connectivity is also seen 
in patients with SZ (Kraguljac et al., 2016) and genetic rodent models relevant to the 
disorder (Dawson et al., 2015; Sigurdsson et al., 2010). Again a central role for altered 
neuromodulatory system connectivity is indicated as a result of prolonged NMDA receptor 
hypofunction, with decreased PFC - LC connectivity supported (Dawson et al., 2012).  
Insights from human studies characterising brain network connectivity alterations induced 
by NMDA receptor antagonists  
 
Graph theory approaches to characterising altered brain network connectivity have been 
widely applied in relation to brain network connectivity in SZ patients (Hadley et al., 2016; Li 
et al., 2008; Micheloyannis et al., 2006; van den Heuvel, 2010) and in a range of other 
cognitive brain disorders. However, very few studies have applied graph theory network 
analysis in the context of pharmacologically induced NDMA-R hypofunction in HCs.  For 
example, using task-free pharmacological MRI Joules et al., report increased degree 
centrality, indicative of the number of functional connections a given region has in the 
context of the brain network, for the basal ganglia and decreased centrality for cortical 
regions, including regions in the frontal cortex, following ketamine administration (Joules et 
al., 2015). No other graph theory measures were reported as a part of this study and the 
authors themselves highlight the additional insight that the application of these additional 
measures could give. The data driven approach taken in this study highlights the value of 
using graph theory approaches to define alterations in network connectivity. The reduced 
PFC connectivity induced by ketamine administration in this study contrasts with the 
increased PFC connectivity reported using FC analysis in HCs by others (Anticevic et al., 
2015) and the preclinical data that support the general enhancement of PFC connectivity 
following ketamine administration (Dawson et al., 2014). The reasons for this disparity 
remain unclear, but may include the use of only one form of connectivity analysis in the 
Joules et al., study (degree centrality) or that the regions of interest that were included in 
the analysis influenced the findings (as ketamine treatment has been shown to increase and 
decrease PFC connectivity to different brain regions (Dawson et al., 2013). For example, 
another recent study used a seed regional approach to characterising the impact of 
ketamine on PFC-hippocampal connectivity in HCs, supporting a ketamine-induced increase 
in the functional connectivity between these neural subsystems (Grimm et al., 2015). 
Interestingly, this investigation also confirmed similar effects in rodents using the same 
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approach, further highlighting the translational value of measuring functional brain network 
connectivity. 
 
As the application of graph theory methods in the context of NMDA receptor antagonist 
induced alterations in brain network FC are relatively limited, here we also consider the 
effects on task-based FC from fMRI studies. To date the vast majority of these studies have 
been applied in the context of the influence of NMDA receptor antagonists during working 
memory tasks, which has potential translational confounds when attempting to compare 
the observed effects to those seen in resting state brain imaging data. However, overall the 
effects reported seem similar to those found when brain imaging is undertaken at rest, and 
in animal models. For example, Driesen et al. found that acute ketamine administration 
significantly reduced FC between the DLPFC and middle frontal gyrus (MFG), and impaired 
performance, during working memory function in HC (Driesen et al. 2013b). In a more 
recent study, dextromethophan led to increased FC within a brain network comprising 270 
seed regions involving the DLPFC (Braun et al., 2016). The findings parallel the increased 
DLPFC FC seen during working memory function in patients with SZ (Siebenhuehner et al., 
2013). Anticevic et al., 2012 also found that ketamine administration increased task-based 
FC in the fronto-parietal network and reduced task-deactivated FC of the default mode 
network (DMN) network during a working memory task (Anticevic et al., 2012), which also 
appear to be similar to effects seen in patients with SZ. To date only these three studies 
have reported the effects of NMDA receptor antagonists on alterations in task-based FC in 
HC. More research into the impact of NMDA receptor antagonists, and other glutamatergic 
compounds, on working memory and brain network connectivity is needed in order to gain a 
better understanding of the effects of glutamatergic modulators on cognitive function, and 
their role in SZ. Multi-modal studies during cognitive function, with the simultaneous 
measurement of glutamatergic concentrations (using Magnetic Resonance Spectroscopy 
(MRS)) in combination with BOLD fMRI may lead to greater insight into glutamatergic 




The glutamatergic system plays a primary role in the regulation of multiple domains of 
cognition. Targeting glutamatergic neurotransmission offers hope for the treatment of 
cognitive deficits seen in patients with SZ and other brain disorders with pronounced 
cognitive deficits. Characterising the impact of modified glutamate system function on brain 
network connectivity offers new systems-level insight into the mechanisms underlying the 
glutamatergic regulation of cognition. The study of how functional brain networks are 
modulated by glutamateric neurotransmission is in its extreme infancy. Here we have 
outlined recent studies that have characterized the impact of NMDA receptor antagonists 
on brain network connectivity as a leading exemplar of the new insight that can be gained 
from the study of how the glutamate system modulates brain network connectivity and 
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cognition. Taking this approach may have great translational value, as initial observations 
appear to be conserved across different species and imaging modalities. Future studies 
dedicated to studying the effects of other procognitive compounds and modifications of 
glutamate system function, whether they be pharmacological or genetic, should be 
undertaken in order to further understand the mechanisms through which these 
manipulations elicit their effects on cognition.  
 
Nomenclature of Targets and Ligands 
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Southan et al., 2015a; 2015b; 2016), and are permanently archived in the Concise 































Table 1. Cognitive deficits reported in genetic mouse models targeting the NMDA receptor 










Barkus et al., 2012 
Impaired short-term object 
recognition memory 
Impaired spatial reference 
memory 
Impaired learning in a visual 
discrimination task 
Ablation of GluN1 
in cortical 
excitatory neurons 
of mPFC and 
SSCTX 
Impaired short-term object 
recognition 
Rompala et al., 2013 Normal spatial working 
memory 
Ablation of GluN1 
in HP (DG and 
CA1) 
Impaired in spatial reversal 
learning (water maze) Taylor et al., 2014 Not impaired in spatial 
discrimination (water maze) 




No deficit in cognitive 
flexibility, working memory or 
attentional processing 
Bygrave et al., 2016 
GluN2A 
GluN2A KO mice 
Impaired spatial working 
memory Bannerman et al., 2008 No impairment in long term 
spatial reference memory 
GluN2A KO mice 
Impaired extra-dimensional set 
shifting Marquardt et al., 2014 Not impaired in discrimination 
or reversal learning 
GluN2A KO in HP 
and CTX Impaired reversal learning Thompson et al., 2015 
GluN2B 
GluN2B KO in 
principal neurons of 
the postnatal 
forebrain 
Impairment in spatial working 
memory, spatial reference 
memory, impaired recognition 
memory, performance deficits 
in simple Morris water maze 
and visual discrimination tasks 
von Engelhardt et al., 2008 
GluN2B KO in HP 
(CA1 and DG)  
Impaired spatial working 
memory and reversal learning 
von Engelhardt et al., 2008 No impairment in spatial 
reference memory 
GluN2C GluN2C KO mice 
Deficit in fear conditioning and 
spatial working memory Hillman et al., 2011 
No impairment in spatial 
reference memory 
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GluN2D GluN2D KO mice 
Impaired social memory 
Yamamoto et al., 2017 No impairment in novel object 
recognition 
GluN3A GluN3A KO mice 
Improved spatial learning and 
enhanced object recognition 
memory 
Mohamad et al., 2013 
GluN3B GluN3B KO mice 
No difference in spatial 
reference memory and fear 
conditioning 
Niemann et al., 2007 











































Table 2. Impact of NMDA-R antagonist administration on cognitive functions in human controls 
 






Study design/ Drug 
administration 
Task design for cognitive 
function 
Main findings - Effects of drug on cognition 
and/or neural response measures during 
cognition 




N (M:F) Mean age in 
years (SD) 
   
Contingency Learning 
Vinckier et al. 
2016 
N/A HC 




subjects study design 




● Ketamine: low-dose 
bolus and iv. 
injection 
● Placebo: Saline 
fMRI: 
Probabilistic learning task – 
parametric modulation. 
1. GLM: Separation of 
categorical regressors for 
cue and outcome onsets 
2. GLM: Outcome onsets 
modulated by two 
computational variables 
(ROI analysis) 
Effect of ketamine on cognitive performance: 
● Ketamine decreases optimisation of outcomes 
given misleading unexpected outcomes 
Effect of ketamine on BOLD response: 
● Altered BOLD response in fronto-parietal 
regions based on contingency learning, mostly 
in regions of the cerebellum, MFG, DLPFC and 
inferior parietal cortex in ketamine when 
compared to placebo (ROI analysis) 
 
 
Corlett et al. 
2006 
N/A HC 




subjects study design 




● Ketamine: low-dose 
bolus and iv. 
fMRI: 
Associative learning task. 
• Associative relationships 
• Prediction error 
Effect of ketamine on cognitive performance: 
● No difference in behavioural performance 
between ketamine and placebo 
Effect of ketamine on BOLD response: 
● Increased BOLD response in the right PFC in 
response to expected stimuli in ketamine 




Injection while in 
scanner 
● Ketamine: high-dose 
bolus and i.v. 
injection outside of  
● Placebo: Saline 
Working memory and declarative memory 
Krystal et al. 
2005 
N/A HC – Amphetamine 
group (14 study 
completers)  
 
HC – Ketamine group 
(13 study completers) 
 
27 (16:11) 
16 Male      33(+8.9) 





● Amphetamine group: 
1) Infusion of 
0.25mg/kg followed 
by saline, 2) 
Ketamine infusion of 
0.23mg/kg, 3) 
Amphetamine 
placebo (saline), 4) 
Ketamine, 5) Placebo 
amphetamine, 6) 
Placebo ketamine.  
● Ketamine group: 




ketamine   
1. CPT 
2. HVLT (6 versions) 
3. PANSS: Cognitive 
symptom score. 
Effect of ketamine on cognitive performance: 
1. Significant effect in accuracy on CPT for 
ketamine but not for amphetamine. 
2. For HVLT immediate recall, there was a 
significant interactive effect of ketamine with 
amphetamine when compared to placebo. 
2. For HVLT delayed recall, there was a significant 
interaction between ketamine and 
amphetamine. 
Honey et al.  
et al. 2008 
N/A HC 




subjects study design 
● Two separate drug 
fMRI: 
1. Working memory (N-Back 
task). Button presses for 
targets and distractors. 
2. CPT (Button press for 
Effect of ketamine on cognitive performance: 
1. Significant effect of ketamine for RT compared 
to placebo. 
2. Significant effect of ketamine for RT compared 





● Ketamine: low-dose 
bolus and iv. 
Injection while in 
scanner 
● Ketamine: high-dose 
bolus and i.v. 
injection outside of  
● Placebo: Saline 
targets but not for 
distractors) 
3. Sentence completion task 
(Button press for task 
completion) 
4. Verbal self-monitoring 
task (Sub-vocalisation during 
sentence completion and 
incompletion) 
Effect of ketamine on BOLD response; 
1. Increased BOLD response of basal ganglia and 
thalamus after ketamine across all working 
memory load conditions with a strong effect for 
2-Back (ROI analysis) 
2. No effect of ketamine observed. 
3. No effect of ketamine observed. 
4. No effect of ketamine observed. 
 
Anticevic et al. 
2012 
N/A HC - Ketamine group 




subjects study design 




● Ketamine: i.v. via 
initial bolus 
0.23mg/kg over 1 
min, followed by 
subsequent infusion 
(0.58mg/kg over 1 
hour)  
● Placebo: 1 saline 
injection 
fMRI (FC): 
Delayed spatial working 
memory task 
Effect of ketamine on cognitive performance: 
● Decreased accuracy for working memory 
versus control trials under ketamine  
Effect of ketamine on BOLD response; 
● Ketamine attenuated task-based activations of 
the DLPFC and precuneus for the working 
memory task and task-based deactivations for 
the DMN. 
Effect of ketamine on FC; 
● Seed-based FC for the seed regions as part of 
the fronto-parietal and the DMN: Significant 
modulation of the task-based FC (delay part of 
the working memory task) and DMN under 
ketamine 
Driesen et al. 
2013b 
N/A HC – Ketamine group 




subjects study design 
● Three separate drug 
challenge sessions 
fMRI (FC): 





Effect of ketamine on cognitive performance: 
● Decreased accuracy for working memory 
versus control trials under ketamine  
Effect of ketamine on BOLD response; 
● Ketamine attenuated task-based activations of 




● Ketamine: i.v. via 
initial bolus 
0.23mg/kg over 1 
min, followed by 
subsequent infusion 
(0.58mg/kg over 1 
hour)  
● Placebo: 1 saline 
injection 
memory task and task-based deactivations for 
the DMN. 
Effect of ketamine on FC; 
1. Decreased FC between right DLPFC and MFG, 
IFG under ketamine when compared to placebo 
 2. Decreased FC within the left DLPFC 
Braun et al. 
2016 
N/A HC – 
Dextromethorphan 
group 




over study design 





120mg in capsule 
form 
● Placebo: capsule 
fMRI (FC): 
N-Back working memory 
task (0-Back and 2-Back 
conditions), Button presses 
for the target stimuli 
Effect of dextromethorphan on cognitive 
performance: 
● No differences for accuracy or RT in the 
working memory task between 
dextromethorphan versus placebo  
Effect of dextromethorphan on FC; 
● FC for 270 regions in terms of network 
flexibility:  
Increased network flexibility under 
dextromethorphan when compared to placebo 
Visual Attentional Processing 
Watson et al. 
2009 
N/A HC 





● Three separate drug 
challenge sessions:  
● Saline (placebo) 
● Ketamine (0.23mg/kg 





Effect of ketamine on thiopental on cognitive 
performance:     
● Decreased target RT after thiopental and ketamine 
when compared to placebo; stronger effect in 
thiopental 
Effect of ketamine and thiopental on ERPs: 
●  Decreased target P3b amplitude at electrode Pz after 
ketamine versus placebo 
● Decreased target P3b amplitude at electrode Pz after 
23 
● Thiopental (1.5mg/kg 
and infusion rate: 
40mcg/kg/hr) 
thiopental versus placebo 
●  No difference in target P3b amplitude between 
ketamine and thiopental 
● Significant correlations between changes in P3b 
amplitude and target RT after thiopental but not 
ketamine at electrode Pz 








● Two separate drug 
challenge sessions 
(placebo/active drug): 
● Ketamine: (0.24mg/kg 
and infusion rate: 
0.0mg/kg/hr)  
● Placebo: Physiological 
sodium chloride 




during the auditory 
test paradigm 
(MMN) 
Effects of ketamine on cognitive performance: 
● Decreased correct detection of hits after ketamine 
administration compared to baseline 
● Increased false alarms after ketamine 
administration compared to baseline and placebo 
conditions 
Effects of ketamine on auditory ERPs: 
● Decreased peak amplitudes of MMN after ketamine 
in pitch-deviance condition and duration-deviance 
condition compared to baseline condition and 
placebo condition, respectively. 
● Increased N1 peak amplitude after ketamine 




15 (9:6)     38 (Missing) 
 
● Randomized, double-
blind, cross-over study 
design 
● Low and high dose of 
the 5HT2A agonist DMT 








Effects of ketamine on cognitive performance: 
● Low-doses and high-doses of DMT and S-ketamine     
impair behavioural performance during the AX-CPT 
Effects of ketamine on auditory ERPs: 
● Decrease in generation of MMN after S-ketamine > 
DMT 
● Trend decrease in the frequency-deviant-induced 
MMN at electrode Fz after low-dose S-ketamine 
●  Decreased duration-deviant MMN at electrodes Fz, 
F3, F4 after low-dose and high-dose S-ketamine 
 
Abbreviations. BOLD response, Blood oxygen level-dependent response; CPT, Continuous Performance Test; DLPFC, dorsolateral prefrontal cortex; DMN, default-mode 
network; DMT, dimethyltryptamine; FC, functional connectivity; HC, healthy controls; HVLT, Hopkins Verbal Learning Test; IFG, inferior frontal gyrus; MFG, middle frontal 
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gyrus; MMN, Mismatch Negativity; N/A, not applicable; N-methyl-D-aspartic acid (NMDA); PANSS, Positive and Negative Symptoms Scale; PFC, prefrontal cortex; ROI, 
































Table 3. Impact of NMDA-R coagonists and partial agonists on cognition 
 








Study design/ Drug 
administration 
Task design for 
cognitive function 
Main findings - Effects of drug on cognition and/or 
neural response measures during cognition  








   
General Cognition 






27 (24:3)     
45.9(+7.4) 
 
EST – Placebo 
group 









● Randomised double-blind, 
placebo-controlled, parallel 
group study design 
● 6 month trial 
● D-Cycloserine: 50 mg 
capsule at bedtime in 
adjunct with conventional 
antipsychotic medication 
● Placebo: Capsule at 





2. IQ estimation 
(Vocabulary, 
Information, 
Digit Span and 
Block Design) 
3. ANART 
4. Stroop Test 
5. Categories 
6. Finger Tapping 
7. WCST 
Effect of  D-Cycloserine on cognitive performance: 
● No difference between treatment groups on any 
cognitive task at weeks 8, 12 and 24 compared to 
baseline.  
Neumeister 
et al. 2006 
N/A HC 
12 (8:4)      
28.5(+10.5) 
 
● Double-blind, randomised, 
balanced cross-over study 
design 









Effect of glycine on cognitive performance: 
● No significant effect of glycine on any of the 
neuropsychological tests compared to placebo 
Effect of glycine on PET measures: 
● Decreased whole-brain cerebral metabolic rate of 
glucose (CMRGlu) in glycine treated HCs when 
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● Glycine: 200mg/kg body 
weight for 45 mins i.v.   









compared to placebo 
● Decreased rCMRGlu in cerebellum and DLPFC 
without whole-brain correction (ROI analysis)    
Buchanan et 
al. 2007 
























● Three treatment groups 
(pill-based): 
1. Active glycine + placebo D-
cycloserine 
2. Placebo glycine + active D-
cycloserine 
3. Placebo glycine + placebo 
D-cycloserine 
Battery: 
2. Processing speed 
3. Verbal fluency 




7. Visual spatial 
memory 






Effect of glycine on cognitive performance: 
● No difference between glycine and placebo on 
the composite cognition summary score 







et al. 2010 
N/A HC 
45 (45:0)     18-55 
 
Four treatment 




cross-over ascending dose 
study design 
● Scopolamine 0.5mg or 
placebo i.v. for 15 mins and 
0, 3, 10, 30 mg of R213129 
Adaptive tracking, 
finger tapping, 
Stroop test, VVLT    
Effect of scopolamine on cognitive performance: 
● Decrease in all parameters of VVLT with 
scopolamine when compared to placebo 
● Decrease in all parameters of the Stroop test with 
scopolamine when compared to placebo 
27 
or placebo oral 
administration 
Weiser et a. 
2012 
EST - D-serine group 
(adjunctive 
treatment) 
97 (74:23)  39.39 
(+12.0) 
 
EST – Placebo 
group 
98 (70:28)  
39.75(+12.3)      
N/A ● 16 week double-blind, 
randomised, placebo-
controlled study design 
● Over course of study 
between 1.6g/day and 
2g/day of D-serine 
Hebrew version of 
the MATRCIS with 
10 subtests 
Effect of D-serine on cognitive performance: 
● No effect of treatment group or group-by-time 
interaction for the composite score and the 
individual scores 
 
Cain et al. 
2014 
EST - D-Cycloserine 
group (adjunctive 
treatment)  
18 (16:2)     
48.8(+11.5) 
 
EST – Placebo 
group 
18 (15:3)     
46.2(+13.3) 
N/A ● 8 week single-blind, 
randomised, placebo-
controlled study design 
● D-cycloserine 50 mg/week 
or placebo (capsule) 
● Cognitive 
Remediation 
between 3 – 5 








al test battery 
Effect of  D-Cycloserine on cognitive performance: 
●  No difference in auditory discrimination training 
in D-Cycloserine when compared to placebo at 
baseline 
● Increase in auditory discrimination training in D-
Cycloserine when compared to placebo at each 
visit after baseline 
● No difference in the composite sore or individual 
scores of the MATRICS in D-Cycloserine when 
compared to placebo 
● Increase in composite score and individual scores 
of some MATRICS tests in placebo when 
compared to D-Cycloserine 
Christmas et 
al. 2014 
N/A HC – Org 25935 
group 
 
16?(16:0)   
23.8(+Missing) 
 
HC – Placebo grouo 
16?(16:0)   
● Double-blind, randomised, 
placebo-controlled, parallel 
group, single-dose study 
design 
● Org 25935: Oral dose of 
12mg 




● Digit span 
● Verbal memory 
task 
Effect of  Org 25925 on cognitive performance: 
● No difference between the groups in the Manikin 








EST - D-Cycloserine group 
(adjunctive treatment) 
10 (10:0)      48.7 (+5.1) 
 
EST- Placebo group 
12(12:0)       54.5(+6.8) 




• D-cycloserine: 50 
mg (capsule) or 
placebo (capsule) 
1. AX-CPT 




• At baseline, 
after 2 weeks 
and 4 weeks 
• In subgroup of 
7 EST in the D-
cycloserine 




Effect of D-cycloserine on cognitive performance: 
1. No differences in accuracy or RT on the CPT 
between D-cycloserine and placebo at all three 
time points  
2. No differences in accuracy or RT on the 
Sternberg test between D-cycloserine and 
placebo at all three time points  
 
Abbreviations. ANART, Adult North American Reading Test; CVLT, California Verbal Learning Test; EST, patients with established schizophrenia; HVLT, Hopkins Verbal 
Learning Test; N/A, not applicable; N-methyl-D-aspartic acid; NMDA; PANSS, Positive and Negative Symptoms Scale; RT, response time; SD, standard deviation; WCST, 
Wisconsin Card Sorting Test. 
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